Computational & Systems Biology Program
The Dana Pe'er Lab
The Pe’er lab combines single cell technologies, genomic datasets and machine learning algorithms to address fundamental questions in biomedical science. Empowered by recent breakthrough technologies like massive parallel single cell RNA-sequencing, we ask questions such as: How do multi-cellular organisms develop from a single cell, resulting in the vast diversity of progenitor and terminal cell types? How does a cell’s regulatory circuit control the dynamics of signal processing and how do these circuits rewire over the course of development? How does an ensemble of cells function together to execute a multi-cellular response, such as an immune response to pathogen or cancer? We will also address more medically oriented questions such as: How do regulatory circuits go awry in disease? What is the consequence of intra-tumor heterogeneity? Can we characterize the tumor immune eco-system to gain a better understanding of when or why immunotherapy works or does not work? A key goal is to use this characterization of the tumor immune eco-system to personalize immunotherapy.
Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis. Burdziak C*, Alonso-Curbelo D*, Walle T, Reyes J, Barriga FM, Haviv D, Xie Y, Zhao Z, Zhao CJ, Chen HA, Chaudhary O, Masilionis I, Choo ZN, Gao V, Luan W, Wuest A, Ho YJ, Wei Y, Quail DF, Koche R, Mazutis L, Chaligné R, Nawy T, Lowe SW†, Pe’er D†. Science. 2023 May 12;380(6645):eadd5327. PMID: 37167403.
The emergent landscape of the mouse gut endoderm at single-cell resolution. Nowotschin S*, Setty M*, Kuo YY, Liu V, Garg V, Sharma R, Simon CS, Saiz N, Gardner R, Boutet SC, Church DM, Hoodless PA, Hadjantonakis AK†, Pe’er D†. Nature. 2019 May;569(7756):361-367. PMID: 30959515
Characterization of cell fate probabilities in single-cell data with Palantir. Setty M, Kiseliovas V, Levine J, Gayoso A, Mazutis L, Pe’er D. Nat Biotechnol. 2019 Apr;37(4):451-460. doi: 10.1038/s41587-019-0068-4. PMID: 30899105.
Dana Pe'er, PhD
Chair, Computational and Systems Biology Program, SKI; Scientific Director, Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center; Investigator, Howard Hughes Medical Institute; Alan and Sandra Gerry Endowed Chair
- Computational Biologist Dana Pe’er combines single cell technologies, genomic datasets and machine learning techniques to address fundamental questions addressing regulatory cell circuits, cellular development, tumor immune eco-system, genotype to phenotype relations and precision medicine.
- PhD, Hebrew University, Jerusalem Israel
- [email protected]
- Email Address
- PhD, University of Paris – XI / Institute Gustave Roussy, France (Oncology)
- BS, Évry Val d’Essonne University, France (Cellular Biology and Physiology)
- PhD, University of Cambridge, UK (Medical Sciences)
- MSc, University of York, UK (Computational Biology and Bioinformatics)
- BSc, Universidad Nacional Autónoma de México, Mexico (Biomedicine)
- BS, Duke University
- PhD, California Institute of Technology
- MD, David Geffen School of Medicine at UCLA
- Internal Medicine Residency, Massachusetts General Hospital
- Oncology Fellowship, Dana Farber Cancer Institute/Massachusetts General Hospital
- BA, Columbia University (Neuroscience and Applied Statistics)
- PhD in Computational Biology, Cornell University, Ithaca NY USA
- Minor: Computer Science (Concentration: Machine learning)
- BSc in Biochemistry, The Chinese University of Hong Kong, Hong Kong
- PhD, Francis Crick Institute/Imperial College London (Computational Biology)
- MSc, University of Warwick (Mathematics of Complex Systems)
- MMath, University of Warwick (Mathematics)
- BS, Emory & Henry College
- PhD, Strasbourg University (Biological Chemistry)
- BS, Vilnius University
- PhD, Weill Cornell Graduate School, New York (Systems Biology)
- MS, Columbia University, New York (Computer Science)
- BEng, National Institute of Technology, Karnataka, India (Computer Engineering)
- 2023 Class of 2023 Inductee - American Academy of Cancer Research (AACR) Academy
- 2023 Innovator Award - International Society for Computational Biology (ISCB)
- 2021 Fellow - International Society for Computational Biology (ISCB)
- 2019 Ernst W. Bertner Memorial Award - University of Texas MD Anderson Cancer Center
- 2016 Lenfest Distinguished Faculty Award - Columbia University
- 2014 Director’s Pioneer Award - National Institutes of Health
- 2014 Overton Prize - International Society for Computational Biology (ISCB)
- 2012 Test of Time Award - Research in Computational Molecular Biology (RECOMB)
- 2010 Innovator Award - Stand Up 2 Cancer/American Academy of Cancer Research (AACR)
- 2009 Packard Fellowship in Science and Engineering - The David and Lucile Packard Foundation
- 2007 NIH Director's New Innovator Award - National Institutes of Health
- 2005 Breakthrough of the Year Runner-up - Science Magazine
- 2005 Career Award at the Scientific Interface - Burroughs Wellcome Fund
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dana Pe'er discloses the following relationships and financial interests:
Equity; Professional Services and Activities
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.